Recent Quotes (30 days)

You have no recent quotes
chg | %

YM BioSciences Inc.  

(Public, TSE:YM)   Watch this stock  
Find more results for YM
- Close
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week     -
Open     -
Vol / Avg. 0.00/205,698.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -0.22
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q4 (Dec '12) 2012
Net profit margin -293.37% -1897.57%
Operating margin -293.37% -1897.57%
EBITD margin - -1861.20%
Return on average assets -36.36% -18.18%
Return on average equity -41.19% -21.39%
Employees 32 -
CDP Score - -


Building 11 Suite 400, 5045 Orbitor Dr
+1-905-6299761 (Phone)
+1-905-6294959 (Fax)

Website links


YM BioSciences Inc. (YM), is a drug development company. The Company is advancing three clinical-stage hematology and cancer-related products. Its CYT387, is an oral small molecule oral dual inhibitor of the JAK1/JAK2 kinase; nimotuzumab, an EGFR-targeting monoclonal antibody, and CYT997, a vascular disrupting agent (VDA). The Company conducts and outsources clinical trials and also out source the manufacture of clinical materials to third parties. It focuses to co-develop and/or license the rights to manufacture or market its products in development to other pharmaceutical companies in exchange for license fees and royalty payments. YM�s portfolio contains a library of novel small molecules with development potential.